肿瘤精准医疗合作与授权协议（2016-2025）

本报告全面深入分析了肿瘤精准医疗合作与许可协议，让您以前所未有的方式了解全球领先的生物製药公司签署的肿瘤精准医疗协议。

这份经过全面修订和更新的报告详细介绍了2016年至2025年间的肿瘤精准医疗交易。

本报告详细分析了企业达成肿瘤精准医疗协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作、开发、研究和授权等内容。

本报告列出了自2016年以来宣布的879项肿瘤精准医疗交易。报告尽可能包含财务条款，并提供连结指向各方揭露的实际肿瘤精准医疗合作交易的线上记录。此外，在可取得的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了肿瘤精准医疗领域的交易情况。

第一章概述了本报告。

第二章概述了自2016年以来肿瘤精准医疗领域的交易活动。

第三章概述了自2016年以来主要的肿瘤精准医疗交易，并依交易额列出。

第四章提供了肿瘤精准医疗交易领域最活跃的25家公司的完整列表，并附有简要概述。随后是肿瘤精准医疗交易的完整清单以及公开合约文件清单。

第五章对自2016年1月以来已完成或宣布的肿瘤精准医疗交易进行了全面深入的回顾，重点关注合约文件公开的案例。

第六章对自2016年1月以来已完成或宣布的肿瘤精准医疗合作交易进行了全面深入的回顾。本章依肿瘤精准医疗技术的具体类型进行组织。

本报告也包含大量表格和图表，显示了自2016年以来肿瘤精准医疗交易的趋势和动态。

此外，我们还提供了一个全面的合约目录，依公司名称（依字母顺序排列）、合约类型和治疗靶点进行分类。每个合约标题都连结到合约记录的线上版本，并在可用的情况下连结到合约文件，方便用户根据需要轻鬆存取每个合约文件。

主要优势

本报告 "肿瘤精准医疗合作研究与授权协议" 为读者提供以下主要优势：

• 了解自 2016 年以来的交易趋势
• 浏览肿瘤精准医疗合作与授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 首付款、里程碑付款、特许权使用费
• 依公司（A-Z）、协议类型和治疗领域分类的合约目录
• 以价值排名的主要交易
• 最活跃的交易撮合者
• 识别每笔交易的资产和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作公司的适用性
• 节省数百小时的研究时间

范围

• "肿瘤精准医疗合作与许可协议" 报告旨在帮助读者深入了解肿瘤精准医疗的发展趋势以及全球主要生物製药公司达成的协议结构。

本报告涵盖：

• 生物製药产业肿瘤精准医疗交易趋势
• 製药和生物技术公司肿瘤精准医疗交易记录目录
• 以交易金额排名的主要肿瘤精准医疗交易
• 最活跃的肿瘤精准医疗许可协议
• "肿瘤精准医疗合作研究与许可协议" 报告提供对现有协议记录的全面访问，包括合约文件（如有）。

分析协议有助于对以下方面进行尽职调查：

• 协议具体授予或选择哪些权利？
• 协议实际授予合作伙伴哪些权利？
• 授予了哪些排他性权利？
• 交易的付款结构是什么？
• 如何进行销售和付款审计？
• 合约期限是多久？
• 如何定义合约的关键条款？
• 如何处理和归属知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 如何就分授权和分包条款达成协议？
• 贵公司要求使用哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司合约受哪个司法管辖区管辖？

目录

摘要整理

第一章：引言

第二章：肿瘤精准医疗交易趋势

• 引言
• 历年肿瘤精准医疗交易趋势
• 肿瘤领域最活跃的精准医疗交易商
• 依交易类型划分的肿瘤精准医疗交易趋势
• 依行业划分的肿瘤精准医疗交易趋势
• 依行业划分的肿瘤精准医疗交易趋势
  • 肿瘤精准医疗交易趋势的核心价值
  • 肿瘤精准医疗预付款安排
  • 肿瘤精准医疗交易里程碑付款
  • 肿瘤精准医疗特许权使用费费率

第三章：精准医疗引领肿瘤交易

• 引言
• 肿瘤领域顶尖精准医疗交易

第四章：肿瘤领域最活跃的精准医疗交易撮合者

• 引言
• 肿瘤领域最活跃的精准医疗交易撮合者
• 肿瘤领域最活跃的精准医疗公司简介

第五章：肿瘤领域精准医疗交易目录

• 引言
• 肿瘤领域精准医疗交易目录

第六章：肿瘤领域精准医疗交易 - 依技术类型分类

• 交易目录
• 肿瘤领域精准医疗交易目录（依公司名称，A-Z）
• 交易目录 - 肿瘤精准医疗交易（依交易类型）
• 交易目录 - 肿瘤精准医疗交易（依治疗领域）
• 交易类型定义
• 关于研究公司
• 当前合作伙伴关係
• 当前协议
• 依目前合作伙伴关係划分的最新报告标题

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse precision medicine in oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

• Trends in precision medicine in oncology dealmaking in the biopharma industry
• Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
• The leading precision medicine in oncology deals by value
• Most active precision medicine in oncology licensing dealmakers
• Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

• 2.1. Introduction
• 2.2. Precision medicine in oncology deals over the years
• 2.3. Most active precision medicine in oncology dealmakers
• 2.4. Precision medicine in oncology deals by deal type
• 2.5. Precision medicine in oncology deals by therapy area
• 2.6. Precision medicine in oncology deals by industry sector
• 2.7. Deal terms for precision medicine in oncology deals
  • 2.7.1 Precision medicine in oncology deals headline values
  • 2.7.2 Precision medicine in oncology deal upfront payments
  • 2.7.3 Precision medicine in oncology deal milestone payments
  • 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

• 3.1. Introduction
• 3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine in oncology dealmakers
• 4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine in oncology deals since 2016
• Figure 2: Active precision medicine in oncology dealmaking activity - 2016 - 2025
• Figure 3: Precision medicine in oncology deals by deal type since 2016
• Figure 4: Precision medicine in oncology deals by therapy area since 2016
• Figure 5: Precision medicine in oncology deals by industry sector since 2016
• Figure 6: Precision medicine in oncology deals with a headline value
• Figure 7: Precision medicine in oncology deals with an upfront value
• Figure 8: Precision medicine in oncology deals with a milestone value
• Figure 9: Precision medicine in oncology deals with a royalty rate value
• Figure 10: Top precision medicine in oncology deals by value since 2016
• Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2025
• Figure 12: Precision medicine in oncology deals by technology type since 2016